Wiskott-Aldrich Syndrome (WAS) (thrombocytopenia, Infection, Eczema)

By

Overview

Wiskott–Aldrich syndrome (WAS) is a rare X-linked recessive primary immunodeficiency disorder characterized by abnormalities in platelet production and function, immune system dysfunction, and eczema. Because of its X-linked inheritance pattern, WAS predominantly affects males.

The disease is classically associated with a triad of clinical manifestations:

  1. Thrombocytopenia: A reduced platelet count with abnormally small platelets (microthrombocytopenia), resulting in an increased risk of bruising, petechiae, and bleeding.

  2. Recurrent infections: Impaired immune function involving both T and B lymphocytes, leading to increased susceptibility to bacterial, viral, and fungal infections.

  3. Eczema: An inflammatory skin condition resembling atopic dermatitis, characterized by dry, itchy, erythematous, and scaly skin lesions.

Mnemonic: TIE

  • T – Thrombocytopenia

  • I – Infections

  • E – Eczema

Although TIE is a useful mnemonic for remembering the classic triad, it is not the standard medical abbreviation for the syndrome, which is WAS.

Genetic Basis and Pathophysiology

Wiskott–Aldrich syndrome is caused by pathogenic variants in the WAS gene, located on the short arm of the X chromosome at Xp11.23.

This gene encodes the Wiskott–Aldrich syndrome protein (WASP), a key regulator of actin cytoskeleton organization in hematopoietic cells.

WASP plays an essential role in several cellular processes, including:

  • Actin cytoskeleton rearrangement and cell motility.

  • Intracellular signaling and immune cell activation.

  • Formation and maintenance of immunological synapses.

  • T-lymphocyte and B-lymphocyte function.

  • Platelet formation and normal hematopoietic cell function.

Deficiency or dysfunction of WASP disrupts immune cell signaling, migration, and interactions, resulting in combined immunodeficiency and platelet abnormalities.

The clinical severity varies depending on the underlying genetic variant and residual WASP expression.

Clinical Manifestations

1. Thrombocytopenia (Microthrombocytopenia)

Thrombocytopenia is a hallmark of WAS and is frequently present early in life.

Unlike many other causes of thrombocytopenia, WAS is typically characterized by both a decreased platelet count and reduced platelet size.

Common manifestations include:

  • Petechiae and purpura.

  • Easy bruising.

  • Epistaxis (nosebleeds).

  • Prolonged bleeding following minor injuries.

  • Bloody diarrhea or gastrointestinal hemorrhage.

  • Intracranial hemorrhage in severe cases.

The bleeding tendency is primarily related to the reduced number of circulating platelets, with additional contributions from platelet abnormalities.

2. Recurrent Infections (Immunodeficiency)

WAS causes a combined immunodeficiency affecting both cellular and humoral immunity.

Defects in T-cell activation, B-cell responses, and other immune cell functions increase susceptibility to recurrent and potentially severe infections.

Common infections include:

  • Recurrent otitis media.

  • Sinusitis.

  • Pneumonia.

  • Skin and soft tissue infections.

  • Viral infections, including herpesvirus infections.

  • Opportunistic fungal infections in severe cases.

Characteristic immunological abnormalities may include reduced IgM levels, elevated IgA and IgE levels, variable IgG concentrations, and impaired antibody responses to polysaccharide antigens.

3. Eczema

Eczema is a common manifestation of WAS and may range from mild dermatitis to severe, persistent inflammatory skin disease.

Typical features include:

  • Erythematous, itchy skin lesions.

  • Dryness and scaling.

  • Recurrent inflammatory flares.

  • Secondary bacterial skin infections.

Eczema may be particularly difficult to control in patients with severe immunodeficiency.

Additional Complications

In addition to the classic triad, patients with WAS are at increased risk of developing:

Autoimmune disorders

  • Autoimmune hemolytic anemia.

  • Immune-mediated thrombocytopenia.

  • Vasculitis.

  • Inflammatory arthritis.

  • Inflammatory bowel disease–like manifestations.

Malignancies

  • Lymphoma, particularly B-cell non-Hodgkin lymphoma.

  • Other hematological malignancies.

The risk of autoimmune complications and malignancy generally increases with age, particularly in patients who have not received definitive treatment.

Treatment and Management

Management of Wiskott–Aldrich syndrome involves both definitive treatment aimed at correcting the underlying hematopoietic defect and supportive measures to prevent or manage complications.

1. Hematopoietic Stem Cell Transplantation (HSCT)

Allogeneic hematopoietic stem cell transplantation (HSCT) is the established curative treatment for WAS.

HSCT replaces the patient's defective hematopoietic stem cells with healthy donor-derived cells capable of producing functional immune cells and platelets.

Successful transplantation can:

  • Restore immune function.

  • Correct thrombocytopenia.

  • Reduce the frequency and severity of infections.

  • Improve eczema.

  • Reduce the risk of future autoimmune and malignant complications.

Outcomes are generally better when transplantation is performed early, before significant organ damage or severe complications develop.

HSCT should be considered early in the management of patients with clinically significant WAS, with decisions guided by disease severity, donor availability, and transplant-related risks.

2. Gene Therapy

Gene therapy is an important therapeutic approach for WAS, particularly in patients who lack a suitable stem cell donor.

It generally involves:

  1. Collecting the patient's own hematopoietic stem cells.

  2. Introducing a functional copy of the WAS gene into these cells, commonly using a lentiviral vector.

  3. Administering conditioning treatment.

  4. Reinfusing the genetically modified stem cells to restore WASP expression.

Clinical studies have demonstrated improvements in immune function, bleeding manifestations, and other disease-related complications.

However, gene therapy remains a specialized treatment, and its availability and regulatory status vary by country. Long-term monitoring is essential to assess treatment durability and safety.

3. Supportive and Symptomatic Treatment

Supportive treatment aims to control symptoms, reduce complications, and improve quality of life.

Prevention and treatment of infections

  • Prompt antibiotic treatment of bacterial infections.

  • Immunoglobulin replacement therapy when indicated.

  • Antimicrobial prophylaxis in selected patients.

  • Avoidance of live attenuated vaccines in patients with significant immunodeficiency.

Management of thrombocytopenia

  • Platelet transfusions for severe or life-threatening bleeding and selected invasive procedures.

  • Avoidance of medications that impair platelet function, such as aspirin and nonsteroidal anti-inflammatory drugs, unless specifically indicated.

  • Bleeding precautions and appropriate monitoring.

Management of eczema

  • Regular use of emollients and moisturizers.

  • Topical corticosteroids or other anti-inflammatory therapies when appropriate.

  • Prompt treatment of secondary bacterial skin infections.

Management of autoimmune complications

  • Immunomodulatory treatment tailored to the specific autoimmune manifestation.

  • Careful monitoring for treatment-related infectious complications.

Splenectomy, historically used to improve platelet counts, is generally avoided when possible because it increases the risk of serious infections and does not correct the underlying immunodeficiency.

Key Clinical Points

  • WAS is a rare X-linked recessive disorder caused by pathogenic variants in the WAS gene (Xp11.23).

  • The classic triad is microthrombocytopenia, recurrent infections, and eczema.

  • TIE is a useful mnemonic for remembering these three manifestations.

  • WASP deficiency disrupts actin cytoskeleton regulation and immune cell function.

  • Patients are also at increased risk of autoimmune diseases and hematological malignancies.

  • Allogeneic HSCT is the established curative treatment, while gene therapy offers a promising alternative in specialized settings.

  • Early diagnosis and referral to a specialist center are essential for optimal long-term outcomes.

High-yield clinical pearl: In a male infant presenting with thrombocytopenia, unusually small platelets, recurrent infections, and eczema, Wiskott–Aldrich syndrome should be strongly suspected. The combination of thrombocytopenia and small platelet size is a particularly important diagnostic clue, although platelet size can occasionally be normal.

References: 

Wiskott-Aldrich syndrome (WAS)
https://primaryimmune.org/understanding-primary-immunodeficiency/types-of-pi/wiskott-aldrich-syndrome-was

Identification of six novel WASP gene mutations in patients suffering from Wiskott-Aldrich syndrome
https://pubmed.ncbi.nlm.nih.gov/10737997/

Reference SNP (rs) Report
https://www.ncbi.nlm.nih.gov/snp/rs193922414#publications

Wiskott-Aldrich syndrome: Long-term results of gene therapy developed
https://medicalxpress.com/news/2026-09-wiskott-aldrich-syndrome-term-results.html

© 2020-2030 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742 ISBN: 0-9703195-0-9

 

 

Comments

Post a Comment

Popular posts from this blog

Schnitzler Syndrome: A Rare Autoinflammatory Disorder

By
Schnitzler syndrome is a rare, chronic autoinflammatory disease characterized by chronic urticaria (hives), recurrent fever, joint pain, and monoclonal gammopathy (abnormal proteins in the blood). First described by Dr. Liliane Schnitzler in 1972 , this condition is often misdiagnosed, leading to years of untreated symptoms before a correct diagnosis is made. The case report, " A 58-Year-Old Woman With Urticaria, Fever, and Joint Pain " , describes a case that closely aligns with my own experience with this challenging disorder. Key Features of Schnitzler Syndrome Schnitzler syndrome presents with a characteristic set of symptoms, though not all patients experience them in the same way: Chronic Urticaria (Hives) – Persistent, non-itchy or mildly itchy red patches that do not respond to antihistamines. Monoclonal Gammopathy (IgM or IgG type) – Abnormal monoclonal immunoglobulin detected in the blood (most commonly IgM ). Recurrent Fever – Unexplained fever episodes, often...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Acute Flaccid Myelitis (AFM): Understanding the “Polio-like” Illness Affecting the Spinal Cord

By
Acute flaccid myelitis (AFM) is a rare but serious neurological disorder that primarily affects children and results in sudden weakness or paralysis in the limbs. Often referred to as a “polio-like” illness, AFM has drawn growing attention over the past decade due to its similarities with poliomyelitis and its seasonal spikes in reported cases. While AFM remains uncommon, its potential severity—and the uncertainty surrounding its causes—make it an important condition for clinicians, parents, and public health officials to understand. What Is Acute Flaccid Myelitis? AFM is a condition that affects the gray matter of the spinal cord , where it damages motor neurons responsible for muscle movement. This leads to acute, flaccid paralysis , meaning muscles become limp and weak, often without warning. The condition can progress rapidly, and in some cases, the weakness can become long-lasting or even permanent. Although its symptoms resemble those of poliovirus infection, AFM is not cau...
Read more

Very Long-Chain Fatty Acids (VLCFAs) X-ALD and Spinal Muscular Atrophy (SMA): Exploring the Connection

By
Image
Introduction: White Brain Matter, VLCFAs, and X-ALD X-linked Adrenoleukodystrophy (X-ALD) is a rare inherited metabolic disorder and a major cause of progressive neurodegeneration in children—sometimes referred to as “childhood dementia.” Across related conditions, prevalence can range from approximately 1 in 2,000 to 1 in 500,000 newborns. Among its forms, childhood cerebral X-ALD is the most severe, marked by rapid inflammatory demyelination in the brain and often fatal outcomes if not treated early. At the core of X-ALD is a disruption in the metabolism of Very Long-Chain Fatty Acids (VLCFAs). Normally, these fatty acids are broken down in peroxisomes—specialized structures within cells that help maintain metabolic balance. In X-ALD, a mutation in the ABCD1 gene impairs this function, causing VLCFAs to accumulate, particularly in the white matter of the brain, spinal cord, and adrenal glands. This accumulation leads to demyelination, adrenal insufficiency (Addison’s disease), a...
Read more

Polio and Post-Polio Syndrome (PPS): Summary and Key Insights

By
Image
Abstract Post-Polio Syndrome (PPS) develops in some survivors of paralytic poliomyelitis decades after recovery and is characterized by new or progressive muscle weakness, fatigue, pain, and reduced endurance. The prevailing pathophysiological model attributes PPS primarily to the gradual deterioration of enlarged motor units formed through compensatory axonal sprouting after the initial poliovirus (PV) infection. Although immune dysregulation and chronic systemic inflammation have been investigated as potential mechanisms, current evidence does not support classifying PPS as a primarily dysimmune or chronically inflammatory disorder. Nevertheless, the possible persistence of poliovirus-derived material and its biological significance remain subjects of investigation. Evidence for viral persistence has been reported in subsets of patients with PPS. In one study of 47 patients, elevated anti-poliovirus IgM antibodies were detected in some individuals, with titers reaching 1:250 compared...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By
Image
My Journey Toward Understanding Spinal Muscular Atrophy (SMA) Today, I better understand why Spinal Muscular Atrophy (SMA) received so little attention, particularly during the 1950s. This complex and debilitating genetic disorder was poorly understood, and patients’ symptoms could easily be minimized, misinterpreted, or dismissed. Even today, SMA can present significant diagnostic challenges, particularly in adults with complex medical histories. In my own experience, comprehensive investigations into the underlying cause of progressive muscle weakness were not always pursued. A Long and Complicated Diagnostic Journey In 2008, while being investigated for permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II .  I underwent surgery in 2009, but unfortunately, my symptoms did not improve. In 2010, a DNA test identified a genetic marker involving the ACTN3 gene . Further information about ACTN3 and its possible relation...
Read more

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By
Image
Important update: My experiences have now been formally verified following several years of dismissal. Vasculitis syndromes: the pathogenic roles of COVID-19 and related vaccinations https://link.springer.com/article/10.1186/s12985-025-03032-x  ----------------------------------------- Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially pres...
Read more

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

By
Image
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening diseases that affect the skin and mucous membranes. They are usually caused by medications, especially antibiotics, antiepileptic drugs, and pain relievers, although infections can also trigger them. SJS involves less than 10% skin detachment, TEN involves more than 30%, and intermediate cases are called SJS/TEN overlap. A person with SJS often encounters primary care providers who have limited understanding of this life-threatening illness and may prescribe inappropriate medications.   The disease develops through a severe immune reaction in which cytotoxic T cells and natural killer cells attack keratinocytes, leading to widespread skin cell death. Several pathways are involved, including granzyme, Fas/FasL, perforin, and inflammatory cytokines such as TNF-α, IL-6, and IFN-γ. Genetic susceptibility also plays an important role, as certain HLA alleles are linked to higher risk in spe...
Read more

The Impact of Acids on Muscular and Vascular Systems: Potential Negative Outcomes

By
This is ongoing research, and updates will be included as soon as they become available. A kidney transplant recipient with acute SARS-CoV-2 infection developed rhabdomyolysis and severe acute kidney injury (AKI) . A muscle biopsy confirmed findings consistent with immune-mediated necrotising myositis. Acid exposure and acid–base imbalances may profoundly affect the muscular and vascular systems. Strong acids from external sources, such as industrial chemicals, can cause corrosive tissue damage, while internal disturbances associated with metabolic disorders may disrupt cellular function and contribute to systemic complications. This article explores the potential effects of external acid exposure and internal acid–base disturbances on muscular and vascular health, including those associated with metabolic or genetic conditions. Because susceptibility to ME/CFS and complications following COVID-19 varies among individuals, further research may help determine whether genetic variant...
Read more

Research Proposal: Investigating Cortical Homunculus Dysfunction and Pain Sensitivity Mapping in ME/CFS and Post-COVID Conditions

By
Image
  1. Background and Rationale The cortical homunculus represents the somatotopic organization of the human body within the primary motor and sensory cortices. This organization reflects the unequal distribution of neural resources, with highly sensitive or finely controlled body regions (e.g., hands, lips, face) occupying disproportionately large cortical areas. Originally described by Wilder Penfield and Edwin Boldrey , this model remains central to understanding how the brain processes sensory input and motor output. ME/CFS and post-COVID conditions frequently involve neurological symptoms such as localized pain, hypersensitivity (hyperalgesia or allodynia), and muscle weakness. While current research focuses on neuroinflammation and autonomic dysfunction, the potential role of somatotopic cortical disruption—particularly involving pain sensitivity—remains insufficiently explored. Given the close functional relationship between the sensory homunculus and the supplementary mot...
Read more